Published in Women's Health Weekly, January 22nd, 2000
In December 1999, the company reported that more than 80% of patients evaluated to date who were enrolled in the trial tested positive by this blood assay. In the Phase II/III clinical trial, for patients tested to date with high-affinity antibodies for LJP 394, 30%, or six out of 20 flares occurred in the drug...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly